ATAI Investor Presentation Deck
SUMMARY
DMX-1002 could
potentially
become a
paradigm-shifting
therapy for Opioid
Use Disorder
Current standard of
care for OUD is
medication therapy,
requiring opioid
substitutes that carry
significant side effects
Current strategies for
withdrawal support
have high rates of
relapse
•
●
C
●
●
●
C
●
●
●
●
●
Disease Modification
Single dose administered
in monitored setting,
providing both withdrawal.
i support and oneiric experience
I with goal of complete remission
DMX-1002 has the potential to become the first & best in-class
treatment for OUD, minimizing risk of relapse
●
Withdrawal Support²
• Therapies given for .
symptomatic
management during
supervised withdrawal.
(detoxification)
●
●
●
●
●
●
●
Medication
Assisted Therapy!
Daily therapy given in
substitution of opioid in
outpatient setting in attempt
to wean off from opioid
.
●
●
● ●
.
● ●
● ●
•
●
●
Therapy
Ibogaine (DMX-1002)
DemeRx
Clonidine
Lofexidine
Methadone
Buprenorphine
Naltrexone
●
●
Source: Global Data, Evaluate Pharma (both as of 2021)
(1) Current Standard of Care
(2) Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings.
●
●
●
e
Mechanism of Action
Mixed MoA
Alpha-2 agonist
Alpha-2 agonist
Mu-agonist
Partial Mu-agonist
Mu-antagonist
●
●
●
●
●
●
●
●
●
Single
Therapeutic
Episode
(~)
(✓
No Opioid Side Minimal Abuse
Effects
Potential
(3)
(₁)
(✓)
(₁)
33
High Adherence
/ Low Risk
of Relapse
✓
● ●
●
● ●
●
●
●
•
●
●
●
●
●●
●
●
●
●
●
●
●View entire presentation